Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

serious adverse events in doses up to 3000 mg.

R7128 demonstrated potent, dose-dependent antiviral activity across four prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance in any dose cohort after 14 days of dosing.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration wi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 Instacare Corp. (OTC Bulletin Board: ... life-enhancing prescription drugs and diagnostics and at home ... leading developer and provider of e-health technologies and ... today that as part of the preparation of ... to add two new Directors and has rejected, ...
(Date:12/17/2009)... -- Express Scripts, Inc. (Nasdaq: ESRX ... management companies in North America, announced today ... association of seizure risk among epilepsy patients ... The study found no evidence that switching ... generic substitution, was associated with increased emergency ...
(Date:12/17/2009)... BioTherapeutics, Inc. (NYSE-Amex: PLX ) today announced ... Sales and Commercial Affairs. In this newly ... responsible for all commercial activities, including pre-launch and ... the collaboration agreement between the Company and Pfizer ... emerge from the Company,s pipeline. Ms. Lauterbach ...
Breaking Medicine Technology:Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 2Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 2Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 4Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 1Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 2Blue Shield of California Makes Understanding Health Care Issues Easier for Consumers 50417 3Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 1Hospira Announces New Contract With MedAssets for Intravenous Solutions Renewal of Infusion Devices Agreement 12851 2Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 1Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 2
... Abeome Corporation, a,Georgia-based biotech company, announced today ... a collaboration with Cato Research Ltd.,its global ... collaboration will help support continued development of ... technology vastly improves the development of,monoclonal antibodies ...
... as the Clinical Gold Standard ... from Decision Resources, WALTHAM, Mass., July 15 ... and advisory firms focusing on pharmaceutical and,healthcare issues, ... of depressive mood episodes in patients who suffer ...
Other Medicine Technology:Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder 2
(Date:12/17/2009)... on prevention, experts say , , THURSDAY, Dec. 17 ... getting better at treating heart attacks and other ... basic rules for preventing them, according to new ... the list: too little exercise, too much weight. ... last year reported no activity vigorous enough to ...
(Date:12/17/2009)... the outbreak is a good time to get vaccinated, ... News) -- As the current wave of H1N1 swine ... urged that everyone get vaccinated in case another outbreak ... the H1N1 flu vaccine have eased, it,s an ideal ... Services Secretary Kathleen Sebelius said during a morning press ...
(Date:12/17/2009)... Reportlinker.com announces that a new ... catalogue: ,, India Healthcare IT Investment ... ,, http://www.reportlinker.com/p0169911/India-Healthcare-IT-Investment-Opportunities-Analysis-and-Forecasts-to-2015.html ,, India Healthcare ... 2015 ,, Summary ,, This ... information and data relating to India healthcare ...
(Date:12/17/2009)... Dec. 17 Today, CDC,s Morbidity and ... that the number of state-level epidemiologists has decreased ... over 10% since 2006. There was also a ... same period, including epidemiology capacity for bioterrorism and ... areas such as occupational health, substance abuse, and ...
(Date:12/17/2009)... Dec. 17 /PRNewswire-Asia/ -- China,s leading high-tech,healthcare group, ... Stock Code: 801) is pleased to announce today ... period under review, the Group,s two,associate companies made ... and NASDAQ;,its key businesses have been strengthened, with ... management operations. , Mr. ...
Breaking Medicine News(10 mins):Health News:Obesity, Inactivity Keeping Heart Health Stats Down 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 3Health News:Swine Flu Wanes, But Future Uncertain 2Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 2Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 3Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 4Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 5Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 6Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 7Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 8Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3
... Chemical peels using either alpha-hydroxy acid or beta-hydroxy acid are ... acne, researchers at the Saint Louis University School of Medicine ... different types of acid peels as therapies for the skin ... fewer side effects and results that lasted a bit longer ...
... expanded major clinical trial involving the use of gene therapy ... treatment is more effective than radiation therapy alone for patients ... part of a $9 million grant from the National Cancer ... of gene therapy to treat prostate cancer. , ...
... to seek restatement of Beth Israel Deaconess,Medical Center audit, ... Douglas T. Linde should apply the same Sarbanes-Oxley,standards used ... role on the board of Beth Israel Deaconess Medical ... Workers East. Linde is,also the president and CFO of ...
... transplant is a life saving treatment option for people ... livers far exceeds the supply. Each year only about ... receive one, and some patients die while waiting. In ... how the current system for allocating donor organs in ...
... 6 Sodium and salt levels in foods and,beverages are ... U.S. food,and beverage industry. Why? In two words -- health ... Reduced or No Sodium or Salt,Foods and Beverages in the ... products, foodservice menu items and beverages. All of,which have been ...
... , Scientists from the University of Bonn are researching ... million years ago. They want to find out how the dinosaurs ... fact such gigantic animals should not have existed. The results of ... the Royal Society B,. , Take 200 milligrammes of dried and ...
Other Medicine News:Health News:Treating acne: 2 different acid peels are both effective, study finds 2Health News:Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer 2Health News:Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer 3Health News:Boston Properties Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News: Mayo Clinic Proceedings contributors discuss impact of donor organ allocation system 2Health News: Mayo Clinic Proceedings contributors discuss impact of donor organ allocation system 3Health News:Sodium Content Foods and Beverages Gain Revenues as Americans are Embracing Low- and No-Sodium Campaigns 2Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: